Comparative Pharmacology
Head-to-head clinical analysis: TALZENNA versus ZEJULA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TALZENNA versus ZEJULA.
TALZENNA vs ZEJULA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor, including PARP1 and PARP2, which plays a role in DNA repair. It traps PARP on single-strand breaks, leading to replication fork collapse, double-strand breaks, and cell death in tumors with homologous recombination repair deficiencies, such as BRCA mutations.
Poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. Inhibits PARP catalytic activity and traps PARP-DNA complexes, leading to accumulation of DNA damage and apoptosis in BRCA-deficient tumor cells.
800 mg orally once daily with or without food.
300 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 90 hours (range 74-109 hours). The long half-life supports once-daily dosing and allows for sustained poly(ADP-ribose) polymerase (PARP) inhibition.
36 ± 13 hours; supports twice-daily dosing; in moderate hepatic impairment (Child-Pugh B), t1/2 prolonged to 58 hours.
Talazoparib is eliminated primarily via biliary/fecal excretion (68.7%) and renal excretion (19.1%). Approximately 11% is excreted unchanged in feces and <1% unchanged in urine.
Renal: 70.9% (11.1% unchanged); fecal: 15.5%; metabolism via carboxylesterases (CES1/CES2) and renal excretion of metabolites.
Category C
Category C
PARP Inhibitor
PARP Inhibitor